TinyGemsBreaks Archive - Page 97 of 100

WednesdayJun 08, 2022 12:16 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Grants DehydraTECH(TM) License to Ireland-Based AnodGen Bioceuticals

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the awarding of a five-year, non-exclusive DehydraTECH(TM) license from its wholly-owned subsidiary, Lexaria Pharmaceutical Corp., to AnodGen Bioceuticals of Ireland. According to the update, the awarded license is valid for the manufacturing and distribution of DehydraTECH-processed cannabinoid active pharmaceutical ingredient (“API”) powders within Europe including the U.K., Australia and New Zealand; including pharmaceutical and medical product applications for psychoactive cannabinoids and medical product applications for non-psychoactive cannabinoids. AnodGen, which has the right to manufacture and sell these API powders to third party companies for their own…

WednesdayJun 08, 2022 11:59 am

TinyGemsBreaks – SRAX Inc.’s (NASDAQ: SRAX) Upcoming Event to Highlight Prominent Names and Companies in Decentralized Web Space

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, today announced that the Sequire Decentralized Web Conference will take place on June 23, 2022. As blockchain, DAOs, NFTS and digital currencies take off around the world with far-reaching potential, SRAX is bringing together a list of influential companies making history in this sector for a full day of presentations. Nearly nine million active small-cap investors were invited to the event, which will feature over 15 decentralized web focused companies and keynotes highlighting prominent names in this space.…

TuesdayJun 07, 2022 11:02 am

TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Acquisition of Entheon Biomedical’s DMT Clinical Study

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has entered an agreement to acquire the largest phase 1 DMT study conducted to date. The acquisition, conducted through Cybin IRL Limited, a wholly owned subsidiary of Cybin, is expected to accelerate Cybin’s CYB004 program timeline by an estimated nine months; CYB004 is Cybin’s proprietary deuterated DMT molecule designed for the potential treatment of anxiety disorders.. The phase 1 N,N-dimethyltryptamine (“DMT”) study is focused on evaluating pharmacokinetics/pharmacodynamics of DMT currently underway and is expected to significantly impact the clinical path forward. Renamed CYB004-E, the phase 1 EBRX-101…

TuesdayJun 07, 2022 10:08 am

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $5M Direct, Private Placement Offerings

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has closed on its registered direct offering and concurrent private placement with a single healthcare-focused institutional investor; the offerings were priced at-the-market under Nasdaq rules. According to the announcement, for the registered direct offering, INM issued 4,079,256 common shares at a purchase price of $0.858 per share (or prefunded warrant in lieu thereof). For the concurrent private placement, InMed issued and sold to the investor 1,748,250 common shares (or prefunded warrant in lieu thereto); those shares were offered at the same purchase price as…

MondayJun 06, 2022 3:32 pm

TinyGemsBreaks – Knightscope Inc. (NASDAQ: KSCP) Earns “In-Process” Rating from US Government FedRAMP Program

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies committed to enhancing U.S. security operations, announced that as part of its efforts to pursue Authority to Authorize (“ATO”) in the Federal Risk and Authorization Management Program (“FedRAMP”), the company achieved “In-Process” status. A government-wide program that promotes the adoption of secure cloud services across the federal government, FedRAMP provides a standardized approach to security assessment and authorization, and provides continuous monitoring for cloud products and services. Knightscope has been working to design a secure, hardened environment specifically to support government clients; as part of those efforts, the company built…

MondayJun 06, 2022 3:11 pm

TinyGemsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) Immune Monitoring Platform ‘Is the Right Technology at the Right Time’

Aditxt (NASDAQ: ADTX) recently entered into a multi-year partnership with Guthy-Renker LLC- affiliated GRS. The partnership focuses on building awareness and visibility among consumers and health care providers for the proprietary AditxtScore(TM) Immune Monitoring Platform. “AditxtScore is the right technology at the right time. Our first application, AditxtScore for COVID-19, delivers timely reports on vulnerability and immune status to SARS-CoV-2 and its known variants, giving consumers and their physicians the data they need to make informed health decisions for themselves and their families,” Aditxt CEO and Co-Founder Amro Albanna was quoted in a recent article. Albanna added that the company’s…

MondayJun 06, 2022 2:04 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Takes First Regulatory Step with FDA for Development of DehydraTECH-CBD in Treating Hypertension

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has successfully filed a pre-Investigational New Drug (“IND”) meeting request letter with the U.S. Food and Drug Administration (“FDA”). According to the update, the FDA has already responded to and confirmed Lexaria’s filing and has provided a target date of July 30, 2022, subject to certain conditions being met. “We are excited to take this important first regulatory step with the FDA for the development of our DehydraTECH-CBD for the treatment of hypertension,” said John Docherty, president of Lexaria. “Submission of this request letter…

MondayJun 06, 2022 1:53 pm

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Announced Addition to Russell 2000(R), 3000(R) Indexes

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, will be joining the Russell 2000 and 3000® Indexes effective later this month, on June 27, 2022, after the market opens. The company was named on a preliminary list of additions posted by FTSE Russell on June 3, 2022. In addition, MULN will be automatically added to the appropriate growth and value indexes. According to the announcement, the Russell indexes are comprised of the 4,000 largest U.S. stocks, based on May 6, 2022, trading status. Membership is for one year and is reassessed every year, with new members released annually. Membership…

MondayJun 06, 2022 1:39 pm

TinyGemsBreaks – Tingo Inc. (TMNA) Reports on Annual Shareholder Meeting Results

Tingo (OTC: TMNA), a leading agri-fintech business in Africa, held its Annual Meeting of Stockholders last week. The meeting, which convened on June 2, 2022, had three agenda items, including the election of director nominees. The report noted that shareholders elected 10 director nominees for one-year terms. The nominees include Adewale Adebayo, John J. Brown, Christophe Francois Charlier, Christopher Cleverly, Gurjinder Johal, Leslie Kasumba, Dozy Mmobuosi, Onyekachi Onubogu, Dakshesh Patel and Derrick Randall. In addition, shareholders unanimously ratified the appointment of Gries & Associates LLC as Tingo’s independent accountants for the 2022 fiscal year and approved the compensation paid to the…

MondayJun 06, 2022 1:11 pm

TinyGemsBreaks – SRAX Inc. (NASDAQ: SRAX) Releases Q4, FY 2021 Financial Report; Announces Partnership with Onassis Holdings (ONSS)

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, is reporting record financial numbers for fiscal year 2021 and Q4 2021. Highlights of the report show that SRA exceeded 2021 guidance of $31.5 million, totaling $28.6 million in revenue with BIGtoken, its former subsidiary, totaling $3.4 million in revenue, and record quarterly revenue of $9.6 million, a 27% increase from the company’s Q3 report and 170% over the previous year period. In addition, SRAX reported record GAAP operating income of $2 million in 2021 compared to a…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (310) 299-1717

TinyGemsBreaks